Literature DB >> 25419401

Effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from transplantation tumors of human colorectal cancer in nude mice.

Yunfei Ge1, Yinlu Ding1, Jianliang Zhang1, Zhanyuan Li2, Zhaoting Li2.   

Abstract

This study was to investigate inhibiting effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from human colon cancer. Results showed that metastasis rates in SU6668+5-Fu group, SU6668 group, 5-Fu group decreased obviously (P<0.01). Compared with 5-Fu group and control group, microvessel density significantly decreased in SU6668+5-Fu group and SU6668 group (P<0.05). Vascular endothelial growth factor and base fibroblast growth factor reduced obviously in SU6668+5-Fu group, SU6668 group and 5-Fu group compared with control group, and there were significant differences among SU6668+5-Fu group, SU6668 group and 5-Fu group (P<0.05). Thus, SU6668 can inhibit liver metastasis from colorectal cancer through anti-angiogenesis, and it would have a synergistic effect in combination with 5-Fu. Therefore, SU6668 combined with 5-Fu could be considered as a safe and effective antitumor strategy.

Entities:  

Keywords:  5-Fu; Neovascularization; colon neoplasm; inbred BALB C; liver metastasis; mice; pathologic

Year:  2014        PMID: 25419401      PMCID: PMC4238521     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  17 in total

1.  [Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].

Authors:  Xiao-ting Jiang; Hou-quan Tao; Shou-chun Zou
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2006-07

2.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Authors:  A D Laird; P Vajkoczy; L K Shawver; A Thurnher; C Liang; M Mohammadi; J Schlessinger; A Ullrich; S R Hubbard; R A Blake; T A Fong; L M Strawn; L Sun; C Tang; R Hawtin; F Tang; N Shenoy; K P Hirth; G McMahon
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

3.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

Authors:  G Folprecht; A Grothey; S Alberts; H-R Raab; C-H Köhne
Journal:  Ann Oncol       Date:  2005-05-03       Impact factor: 32.976

4.  A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

Authors:  Henry Q Xiong; Roy Herbst; Silvana C Faria; Catherine Scholz; Darren Davis; Edward F Jackson; Timothy Madden; David McConkey; Marshall Hicks; Kenneth Hess; Chusilp Arthur Charnsangavej; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

5.  Quality assurance in rectal cancer treatment in the Netherlands: a catch up compared to colon cancer treatment.

Authors:  W van Gijn; P Krijnen; V E P P Lemmens; M den Dulk; H Putter; C J H van de Velde
Journal:  Eur J Surg Oncol       Date:  2009-11-26       Impact factor: 4.424

Review 6.  Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.

Authors:  N Weidner
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Effect of splenectomy on antitumor immune system in mice.

Authors:  Jun Higashijima; Mitsuo Shimada; Motoya Chikakiyo; Tomohiko Miyatani; Kozo Yoshikawa; Masanori Nishioka; Takashi Iwata; Nobuhiro Kurita
Journal:  Anticancer Res       Date:  2009-01       Impact factor: 2.480

8.  Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System.

Authors:  Lalitha R Belur; Kelly M Podetz-Pedersen; Brent S Sorenson; Alice H Hsu; Josh B Parker; Cathy S Carlson; Daniel A Saltzman; S Ramakrishnan; R Scott McIvor
Journal:  Mol Cancer       Date:  2011-02-10       Impact factor: 27.401

9.  Protein kinase inhibitor SU6668 attenuates positive regulation of Gli proteins in cancer and multipotent progenitor cells.

Authors:  Alla Piirsoo; Lagle Kasak; Mari-Liis Kauts; Mart Loog; Kairit Tints; Piia Uusen; Toomas Neuman; Marko Piirsoo
Journal:  Biochim Biophys Acta       Date:  2014-01-10

10.  SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression.

Authors:  Lu Wang; Zhaozhe Liu; Dongchu Ma; Ying Piao; Fang Guo; Yaling Han; Xiaodong Xie
Journal:  Cancer Cell Int       Date:  2013-08-29       Impact factor: 5.722

View more
  3 in total

1.  Incidence and risk factors of chylous ascites after pancreatic resection.

Authors:  Wu Pan; Chen Yang; Shen-Yang Cai; Zhi-Meng Chen; Nan-Sheng Cheng; Fu-Yu Li; Xian-Ze Xiong
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 2.  Multi-kinase inhibitors, AURKs and cancer.

Authors:  Jonas Cicenas; Erikas Cicenas
Journal:  Med Oncol       Date:  2016-04-01       Impact factor: 3.064

Review 3.  Metadherin regulates epithelial-mesenchymal transition in carcinoma.

Authors:  Zhao Wang; Zheng-Yan Tang; Zhuo Yin; Yong-Bao Wei; Long-Fei Liu; Bin Yan; Ke-Qin Zhou; Ye-Qi Nian; Yun-Liang Gao; Jin-Rui Yang
Journal:  Onco Targets Ther       Date:  2016-04-21       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.